Search

Dostarlimab

A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905] … [L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month.

Viloxazine

It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … Viloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant.

Erythrityl tetranitrate

A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

Daprodustat

[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin

Maralixibat

with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.

Idelalisib

co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. … In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils

Celecoxib

[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. … [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Penicillamine

It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties. … Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).

Haemagglutinin-strain B (Victoria-like)

Abrocitinib

[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products, … [L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395]